SinoMab BioScience Limited
中國抗體製藥有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 3681)

INSIDE INFORMATION

PHASE III CLINICAL STUDY OF SM03 (SUCIRASLIMAB) IN RHEUMATOID ARTHRITIS MEETS PRIMARY ENDPOINT

This announcement is made by SinoMab BioScience Limited (中國抗體製藥有限公司) (the "**Company**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 7 April 2020, 8 June 2020, 22 June 2020, 28 September 2020, 27 October 2020 and 30 November 2021 in relation to the latest research and development progress of the Company's flagship product, SM03 (Suciraslimab).

The board of directors (the "**Board**") of the Company is pleased to announce that, the flagship product of the Company, SM03 (Suciraslimab), met its primary endpoint in a phase III clinical study for the treatment of rheumatoid arthritis (RA) in China. The Phase III clinical study is a randomised, multi-centre, double-blind, placebo-controlled study to confirm clinical efficacy and safety in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX).

The primary endpoint is the proportion of participants with an American College of Rheumatology 20 (ACR20) response at week 24. ACR20 is a composite measure for the assessment of rheumatoid arthritis (RA) improvement by American College of Rheumatology, defined as both improvement from baseline of 20% in tender and swollen joint counts, along with 20% improvements in three of the five remaining core set measures: physician global assessment, patient global assessment, pain scale, disability/functional questionnaire and acute phase reactant (C-reactive protein or erythrocyte sedimentation rate).

According to the assessment of the topline data, SM03 (Suciraslimab) was effective in suppressing disease activity and alleviating symptoms of active RA patients receiving methotrexate therapy. Relevant study result shall be published in academic journals/ academic conferences.

The Company's flagship product, SM03 (Suciraslimab), is our self-developed product. Suciraslimab is a global first-in-target anti-CD22 monoclonal antibody for the treatment of RA and other immunological diseases, it adopts a novel mechanism of action, which differentiates itself from the current treatments available in the market.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The Company cannot guarantee that it will be able to ultimately develop and market SM03 (Suciraslimab) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 26 April 2023

As at the date of this announcement, the executive director of the Company is Dr. Shui On LEUNG, the non-executive directors of the Company are Dr. Haigang CHEN, Mr. Xun DONG, Ms. Wenyi LIU, Ms. Jie LIU and Mr. Lei SHI, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.